natgillin/translations-raw huggingface dataset:
thienyl which may be substituted with 1 or 2 substituents selected from the group consisting of halogeno-C1-6 alkyl and halogen, or 
tienil koji može bit supstituiran s 1 ili 2 supstituenta odabranih od skupine koja se sastoji od halogeno-C1-6 alkila i halogena ili
phenyl which may be substituted with 1 or 2 substituents selected from the group consisting of halogeno-C1-6 alkyl and halogen, and W is methylene or ethylene. 
fenil koji može bit supstituiran s 1 ili 2 supstituenta odabranih od skupine koja se sastoji od halogeno-C1-6 alkila i halogena i W je metilen ili etilen.
The compound or a salt thereof according to claim 1, wherein the compound is a compound selected from the group consisting of: 
Spoj ili njegova sol prema zahtjevu 1, pri čemu spoj je spoj odabran od skupine koja se sastoji od:
A pharmaceutical composition for preventing or treating bladder/urinary tract diseases associated with bladder contractions via a muscarinic M3 receptor, comprising the compound or a salt thereof according to claim 1. 
Spoj ili njegova sol prema zahtjevu 6 za uporabu u prevenciji ili liječenju bolesti mjehura/mokraćnog sustava povezanih s kontrakcijama mjehura kroz muskarinski M3 receptor.
The pharmaceutical composition of any of claims 1-5 wherein the crosslinked amine polymer comprises the residue of an amine corresponding to Formula 2b: wherein 
Farmaceutski pripravak prema bilo kojem od patentnih zahtjeva 1-5, gdje umreženi aminski polimer sadrži ostatak amina koji odgovara Formuli 2b:
m and n are independently non-negative integers; 
gdje m i n su nezavisno cijeli brojevi koji nisu negativni;
and R32 are independently hydrogen substituted hydrocarbyl, or hydrocarbyl; 
i R32 su nezavisno vodik supstituiran hidrokarbil ili hidrokarbil;
The scaffold of claim 1, wherein said scaffold approximates the form of a cylinder, cone, screw, rectangular bar, plate, disc, pyramid, granule, ball or cube. 
Struktura platforme sukladno patentnom zahtjevu 1, pri čemu se navedena struktura platforme približava obliku cilindra, konusa, taka, vijka, pravokutne šipke, ploče, diska, piramide, granule, kugle ili kocke.
The scaffold of claim 1, wherein the scaffold assumes a shape to approximate a meniscus for a knee or elbow; a joint; an articular surface of a bone, a portion of a rib cage, a hip, a pelvis, an ear, a nose, a ligament, a bronchial tube or an intervertebral disc. 
Struktura platforme sukladno patentnom zahtjevu 1, pri čemu navedena struktura platforme podrazumijeva oblik koji se približava meniskusu kakvo ima koljeno ili lakat; zglob; površina zgloba kosti, dio prsnog koša, kuk, zdjelica, uho, nos, ligament, bronhijalna cijev ili intervertebralni disk.
The scaffold of claim 1, wherein said scaffold is cylindrical in shape and has a diameter of about 5-25 mm, and a height of about 5-25 mm. 
Strukturna platforme sukladno patentnom zahtjevu 1, pri čemu navedena struktura platforme ima oblik cilindra i ima presjek od oko 5-40 mm, i visinu od oko 5-25 mm.
A chewing gum composition comprising a cannabinoid, wherein the chewing gum composition comprises 25 to 85 % by weight of a gum base, based on the total weight of the chewing gum composition, wherein the cannabinoid is provided in and on voids or pores within a solid material composed of a cellulose, wherein at least 1% by weight to not more than 30 % by weight, based on the total weight of the cannabinoid, in the chewing gum composition is released within 5 minutes after ingestion, and wherein the onset of the release starts within 3 minutes after. 
Pripravak u obliku žvakaće gume koji sadrži kanabinoid, naznačen time što pripravak u obliku žvakaće gume sadrži 25 do 85 %, težinski, gumene podloge, na osnovi ukupne težine pripravka u obliku žvakaće gume, gdje se kanabinoid nalazi u i na šupljinama ili porama unutar čvrstog materijala koji se sastoji od celuloze, gdje se najmanje 1 %, težinski, do najviše 30 %, težinski, na osnovi ukupne težine kanabinoida, u pripravku u obliku žvakaće gume otpušta unutar 5 minuta nakon gutanja, te gdje početak otpuštanja počinje unutar 3 minute nakon toga.
An arrangement for the recycling of carbon and hydrocarbon compounds from organic input material through pyrolysis, comprising: 
Uređaj za recikliranje spojeva ugljika i ugljikovodika iz organskog ulaznog materijala putem pirolize, koji sadrži:
that the gas distribution pipe (121) comprises at least one inlet unit (122.1, 122.2) that demonstrate openings (125) through which gas flows, where the inlet unit (122.1, 122.2) is designed such that the gas distribution pipe demonstrates the form of a truncated cone, 
da cijev za distribuciju plina (121) sadrži najmanje jednu ulaznu jedinicu (122.1, 122.2) koja ima otvore (125) kroz koji plin teće, pri čemu je ulazna jedinica (122.1, 122.2) dizajnirana tako da cijev za distribuciju plina ima oblik krnjeg stošca,
that the openings (125) through which gas flows are distributed with an increasing number of openings in the downwards direction across the lower end of the gas distribution pipe (121), whereby the openings (125, 146, 155, 185) through which gas flows are arranged such that a fall in pressure dP is generated during the supply of gas that exceeds the fall in pressure dM of the gas during passage through the input material M that has been introduced into the chamber. 
da su otvori (125) kroz koji plin teće distribuirani sa sve većim brojem otvora u smjeru prema dolje preko donjeg kraja cijevi za distribuciju plina (121), pri čemu su otvori (125, 146, 155, 185) kroz koje teće plin raspoređeni tako da nastaje pad tlaka dP tijekom isporuke plina koji prelazi pad tlaka dM plina tijekom prolaza kroz ulazni materijal M koji je unesen u komoru.
The arrangement according to claim 1 comprising that the openings (125) through which gas flows are evenly distributed across the peripheral surface (124) of the gas distribution pipe. 
Uređaj prema zahtjevu 1, naznačen time da su otvori (125) kroz koje teće plin ravnomjerno raspoređeni po obodnoj površini (124) cijevi za distribuciju plina.
The arrangement according to any one of the preceding claims, comprising that the openings (125, 155, 185) through which gas flows are arranged to prevent penetration of input material M into the inlet means, whereby each opening (125, 155, 185) through which gas flows demonstrates an upper protruding edge part (125.1) and a lower withdrawn edge part (125.2). 
Uređaj prema bilo kojem od prethodnih zahtjeva, naznačen time da su otvori (125, 155, 185) kroz koje teće plin raspoređeni da se spriječi prodor ulaznog materijala M u ulazna sredstva, pri čemu svaki otvor (125, 155, 185) kroz koji teće plin ima gornji izbočeni rubni dio (125.1) i donji uvučen rubni dio (125.2).
The arrangement according to claim 5 or 6, comprising that the gas inlet means (120) comprises slits (137) that transfer gas arranged along the peripheral edge (131) of the bottom plate. 
Uređaj prema zahtjevu 5 ili 6, naznačen time da sredstva za ulaz plina (120) sadrže proreze (137) koji prenose plin raspoređene duž periferinog ruba (131) donje ploče.
The arrangement according to claims 11-14, comprising that the openings (155) through which gas flows are evenly distributed across the inlet wall surface (150). 
Uređaj prema zahtjevima 11-14, naznačen time da su otvori (155) kroz koje teće plin ravnomjerno raspoređeni po unutrašnjoj površini zida (150).
The arrangement according to claims 11-14 comprising that the openings (155) through which gas flows are distributed with an increasing number of openings in the downwards direction across the inlet wall surface (150). 
Uređaj prema zahtjevima 11-14, naznačen time da su otvori (155) kroz koje teće plin raspoređeni s povećanim brojem otvora u silaznom smjeru po ulaznoj površini zida (150).
The arrangement according to claim 19, comprising that the openings (185) through which gas flows are distributed with an increasing number of openings (185) in the downwards direction across the inlet surface (180) closer to the lower end of each segment (188, 189). 
Uređaj prema zahtjevu 19, naznačen time da su otvori (185) kroz koje teće plin razmješteni s povećanim brojem otvora (185) u silaznom smjeru po ulaznoj površini (180) blizu donjeg kraja svakog segmenta (188, 189).
The arrangement according to claim 22 or 23, comprising that each gap (163.1-163.n) that transfers gas is equipped with particle-blocking means (167) arranged to be extended across of the width of the gap such that input material M that is carried by gas is separated from the pyrolysis gas (107), while the pyrolysis gas is allowed to pass freely through the gap (163.1-163.n). 
Uređaj prema zahtjevu 22 ili 23, naznačen time da je svaki razmak (163.1-163.n) koji prenosi plin opremljen sredstvom za blokiranje čestica (167) smještenim da se pruža preko širine razmaka na način da se ulazni materijal M koji se prenosi putem plina odvaja od plina za pirolizu (107), dok se plinu za pirolizu omogućava da slobodno prođe kroz razmak (163.1-163.n).
The arrangement according to any one of claims 21-24 comprising that outlet surfaces (162.1-162.n) arranged next to each other mutually overlap each other in the vertical direction in order to protect the gaps (163.1-163.n) that transfer gas from penetrating particles of input material M. 
Uređaj prema jednom od zahtjeva 21-24, naznačen time da se ispusne površine (162.1-162.n) koje su smještene jedna kraj druge međusobno preklapaju u okomitom smjeru kako bi zaštitile razmake (163.1-163.n) koji prenose plin od prodirućih čestica ulaznog materijala M.
A method for the recycling of carbon and hydrocarbon compounds from organic input material through pyrolysis, comprising: 
Postupak za recikliranje ugljika i ugljikovodika od organskih ulaznih materijala putem pirolize, obuhvaćajući:
introduction of input material M in fragmented form into a reactor (1) comprising a chamber (110) which is limited by a jacket (111) and upper and lower end-wall sections (112, 113), 
uvođenje ulaznog materijala M u rascjepkanom obliku u reaktor (1) koji obuhvaća komoru (110) koja je ograničena omotačem (111) i gornjim i donjim dijelovima krajnje stijenke (112, 113),
supply through gas inlet means of heated inert gas (101) to the chamber for the pyrolysis treatment of the input material, 
dovod zagrijanog inertnog plina (101) putem sredstava za ulaz plina do komore za pirolizu ulaznog materijala,
The method according to any one of claims 30-32, comprising that the gas is supplied to the input material M that has been introduced into the chamber (110) through a continuous inlet surface (180) that demonstrates openings (185) through which gas flows and that is arranged around the complete inner surface and lower end-wall section of the jacket, where the surrounding peripheral surface of the gas distribution pipe is a part of the inlet surface, whereby the gas is led from the continuous inlet surface through the input material in an upwards direction to a gas outlet pipe arranged at the upper end-wall section. 
Postupak prema bilo kojem od zahtjeva 30-32, naznačen time da je plin doveden do ulaznog materijala M koji je uveden u komoru (110) kroz kontinuiranu ulaznu površinu (180) koja prikazuje otvore (185) kroz koje teće plin i koja je smještena oko kompletne unutrašnje površine i nižeg krajnjeg dijela stijenke omotača, gdje je okolna obodna površina cijevi za distribuciju plina dio ulazne površine, pri čemu je plin vođen od kontinuirane ulazne površine kroz ulazni materijal u uzvodnom smjeru do cijevi za izlaz plina smješten na gornjem krajnjem dijelu stijenke.
The method according to any one of claims 30-33, comprising that the outlet wall surface (165) is heated by pyrolysis gas (107) that is led through the compartment (164) that transfers gas out, whereby condensation of vapourised pyrolysis oil in the input material next to the gas outlet means (160) is prevented. 
Postupak prema bilo kojem od zahtjeva 30-33, naznačen time da je vanjska površina stijenke (165) zagrijana putem plina za pirolizu (107) koji je vođen kroz odjeljak (164) koji prenosi plin prema van, pri čemu je spriječena kondenzacija isparenih ulja pirolize u ulaznom materijalu kraj sredstava za izlaz plina (160).
An antibody molecule capable of binding to human T-cell immunoglobulin domain and mucin domain 3 (TIM-3), comprising: 
Molekula antitijela sposobna vezati se na imunoglobulin domenu humane T-stanice i mucin domenu 3 (TIM-3), koja sadrži:
a human IgG1 heavy chain constant region with an Aspartate to Alanine mutation at position 265 according to EU numbering or position 148 of SEQ ID NO: 113 and Proline to Alanine mutation at position 329 according to EU numbering or position 212 of SEQ ID NO: 113, and a kappa light chain constant region; or 
humanu IgG1 konstantnu regiju teškog lanca s Aspartat na Alanin mutacijom na poziciji 265 prema EU numeraciji ili poziciji 148 SEQ ID NO:113 i Prolin na Alanin mutaciju na poziciji 329 prema EU numeraciji ili poziciji 212 SEQ ID NO: 113, i kappa konstantnu regiju lakog lanca; ili
is capable of binding to human TIM-3 with a dissociation constant (KD) of less than about 0.5 nM; 
sposobna je vezati se na humani TIM-3 uz disocijacijsku konstantu (KD) od manje od oko 0,5 nM;
is capable of reducing: 
sposobna je reducirati:
binding of TIM-3 to phosphatidylserine (PtdSer), HMGB1, CEACAM-1, Semaphorin 4-A, or a combination thereof, or a cell that expresses PtdSer, HMGB1, CEACAM-1, Semaphorin 4-A, or a combination thereof; or 
vezanje TIM-3 na fosfatidilserin (PtdSer), HMGB1, CEACAM-1, Semaforin 4-A ili njihovu kombinaciju, ili stanicu koja izražava PtdSer, HMGB1, CEACAM-1, Semaforin 4-A ili njihovu kombinaciju; ili
PtdSer-mediated membrane penetration of TIM-3; 
penetraciju membrane TIM-3 posredovanu PtdSer-om;
A pharmaceutical composition comprising the antibody molecule of any of claims 1-11 and a pharmaceutically acceptable carrier, excipient or stabilizer. 
Farmaceutski sastav koji sadrži molekulu antitijela prema bilo kojem od zahtjeva 1-11 i farmaceutski prihvatljivi nosač, ekscipijens ili stabilizator.
The nucleic acid of claim 14, comprising: 
Nukleinska kiselina prema zahtjevu 14, koja sadrži:
A method of detecting TIM-3 in a biological sample, comprising (i) contacting the sample or the subject with an antibody molecule of any of claims 1-11 under conditions that allow interaction of the antibody molecule and the polypeptide to occur, and (ii) detecting formation of a complex between the antibody molecule and the sample or the subject. 
Postupak detektiranja TIM-3 u biološkom uzorku, koji sadrži (i) kontaktiranje uzorka ili subjekta s molekulom antitijela prema bilo kojem od zahtjeva 1-11 pri uvjetima koji dozvoljavaju da se dogodi interakcija molekule antitijela i polipeptida, te (ii) detektiranje formiranja kompleksa između molekule antitijela i uzorka ili subjekta.
A method of detecting TIM-3 in a biological sample according to claim 20, wherein step (i) additionally comprises contacting a reference sample or subject with an antibody molecule of any of claims 1-11 under conditions that allow interaction of the antibody molecule and the polypeptide to occur, and step (ii) additionally comprises detecting formation of a complex between the antibody molecule and the reference sample or subject. 
Postupak detektiranja TIM-3 u biološkom uzorku prema zahtjevu 20, pri čemu korak (i) dodatno sadrži kontaktiranje referentnog uzorka ili subjekta s molekulom antitijela prema bilo kojem od zahtjeva 1-11 pri uvjetima koji dozvoljavaju da se dogodi interakcija molekule antitijela i polipeptida, te korak (ii) dodatno sadrži detektiranje formiranja kompleksa između molekule antitijela i referentnog uzorka ili subjekta.
An antibody molecule of any of claims 1-11, or a pharmaceutical composition of claim 12, for use in a method of stimulating an immune response or treating a cancer or an infectious disease in a subject. 
Molekula antitijela prema bilo kojem od zahtjeva 1-11, ili farmaceutski sastav prema zahtjevu 12, za uporabu u postupku stimuliranja imunog odziva ili liječenju raka ili zarazne bolesti u subjektu.
The antibody molecule, or pharmaceutical composition, for use of claim 22, wherein the subject has, or is identified as having, one or more of: 
Molekula antitijela, ili farmaceutski sastav, za uporabu prema zahtjevu 22, pri čemu subjekt ima, ili mu je identificirano da ima, jedno ili više od:
a cancer that expresses TIM-3; 
rak koji izražava TIM-3;
a cancer that is positive for one, two, or all of PD-L1, CD8, or IFN-γ; 
rak koji je pozitivan na jedno, dvoje ili sve od PD-L1, CD8 ili IFN-γ;
a cancer that is triple positive for PD-L1, CD8, and IFN-γ; or 
rak koji je trostruko pozitivan na PD-L1, CD8 i IFN- γ; ili
The antibody molecule, or pharmaceutical composition, for use of claim 22 or 23, wherein: 
Molekula antitijela, ili farmaceutski sastav, za uporabu prema zahtjevu 22 ili 23, pri čemu:
A compound having the formula: for use in a method of treating drug toxicity or overdose in a subject in need thereof. 
Spoj koji sadrži formulu: za uporabu u postupku liječenja toksičnosti lijeka ili predoziranja lijekom kod subjekta kojem je nužno.
A compound for use according to claim 1, wherein said drug toxicity or overdose results from opioid administration to a non-dependent patient. 
Spoj za uporabu sukladno patentnom zahtjevu 1, pri čemu navedena toksičnost ili predoziranje lijekom nastaje kao rezultat primjene opioida pacijentu koji nije ovisnik.
A compound for use according to claim 1, wherein said compound is administered in a daily dose of about 3 to about 20 mg/day. 
Spoj za uporabu sukladno patentnom zahtjevu 1, pri čemu se navedeni spoj primjenjuje u dnevnoj dozi od oko 3 do oko 20 mg/dnevno.
A compound for use according to claim 4, wherein said daily dose is about 10 mg/day. 
Spoj za uporabu sukladno patentnom zahtjevu 4, pri čemu je navedena dnevna doza oko 10 mg/dan.
A compound for use according to claim 1, wherein administration of the compound reduces symptoms of drug toxicity or overdose over a period of at least about 15 to about 30 minutes. 
Spoj za uporabu sukladno patentnom zahtjevu 1, pri čemu primjena spoja smanjuje simptome toksičnosti ili predoziranja lijekom tijekom perioda od najmanje 15 do oko 30 minuta.
A compound for use according to claim 6, wherein symptoms of drug overdose are reduced for a period of at least one hour, a period of at least two hours, a period of at least three hours, a period of at least four hours or a period of at least eight hours. 
Spoj za uporabu sukladno patentnom 6, pri čemu su simptomi predoziranja lijekom smanjeni za period od najmanje jednog sata, period od najmanje dva sata, period od najmanje tri sata, period od najmanje četiri sata ili period od najmanje osam sati.
A compound for use according to claim 6 or claim 7, wherein said administration comprises about 3mg to about 20mg of the compound. 
Spoj za uporabu sukladno patentnom zahtjevu 6 ili patentnom zahtjevu 7, pri čemu navedena primjena sadrži oko 3 mg do oko 20 mg spoja.
A compound having the formula: for use in a method of treating an opioid toxicity or overdose in a subject in need thereof comprising administrating a first opioid receptor antagonist followed by the compound. 
Spoj koji sadrži formulu: za uporabu u postupku liječenja opioidne toksičnosti ili predoziranja kod subjekta kojem je potrebno sadrži isporuku prvog antagonista receptora opioida nakon čega slijedi taj spoj.
A compound for use according to claim 10, wherein said first opioid receptor antagonist is naloxone. 
Spoj za uporabu sukladno patentnom zahtjevu 10, pri čemu je prvi antagonist receptora opioida nalokson.
A compound for use according to claim 10 or claim 11, wherein said subject is an opioid experienced non-dependent opioid user. 
Spoj za uporabu sukladno patentnom zahtjevu 10 ili patentnom zahtjevu 11, pri čemu je navedeni subjekt korisnik opoida koji ima iskustvo s opioidom ali nije ovisnik.
A compound for use according to claim 11, wherein said administration of the compound is preceded by said naloxone administration. 
Spoj za uporabu sukladno patentnom zahtjevu 11, pri čemu nabedenoj primjeni prethodi navedena primjena naloksona.
A compound for use according to claim 13, wherein said naloxone administration reduces symptoms of overdose or toxicity prior to administration of the compound. 
Spoj za uporabu sukladno patentnom zahtjevu 13, pri čemu navedena primjena naloksona smanjuje simptome predoziranja ili toksičnosti prije primjene spoja.
A compound for use according to claim 11, wherein naloxone is administered concurrently with the compound. 
Spoj za uporabu sukladno patentnom zahtjevu 11, pri čemu se nalokson primjenjuje istodobno s tim spojem.
A compound of the Formula: for use in a method of treating acute opioid toxicity or overdose for a period of over one hour comprising a single administration of said compound to a subject in need thereof. 
Spoj od formule: za uporabu u postupku liječenja akutne opioidne toksičnosti ili predoziranja tijemom razdoblja od preko jednog sata sadrži jednokratnu primjenu navedenog spoja subjektu kojem je nužno.
A compound for use according to claim 16, wherein said subject is a non-dependent opioid experienced patient. 
Spoj za uporabu sukladno patentnom zahtjevu 16, pri čemu je navedeni subjekt opioidno iskusan pacijent koji nije ovisnik.
A compound for use according to claim 16, wherein symptoms of opioid toxicity or overdose are reduced for a period of more than one hour, for a period of more than four hours, for a period of more than eight hours or for a period of more than twenty four hours. 
Spoj za uporabu sukladno patentnom zahtjevu 16, pri čemu su simptomi opioidne toksičnosti ili predoziranja smanjeni tijekom razdoblja od više od jednog sata, tijekom razdoblja od više od četiri sata, tijekom razdoblja od više od osam sati ili tijekom razdoblja od više od dvadeset četiri sata.
A compound of the Formula: for use in a method for unmonitored treatment of opioid toxicity or overdose in a patient in need thereof. 
Spoj od formule: radi uporabe u postupku za nekontrolirano liječenje opioidne toksičnosti ili predoziranja opioidom kod pacijenta kojem je nužno.
A compound for use according to claim 19, wherein said unmonitored treatment is effective for a period of over one hour. 
Spoj za uporabu sukladno patentnom zahtjevu 19, pri čemu je navedeno nekontrolirano liječenje djelotvorno tijekom razdoblja od preko jedog sata..
The scaffold of claim 2, wherein said glycosaminoglycan is hyaluronic acid, optionally sodium hyaluronate or cross linked hyaluronic acid. 
Struktura platforme sukladno patentnom zahtjevu 2, pri čemu je navedeni glikozaminoglikan hijaluronska kiselina, izborno natrij hijaluronat ili umrežena hijaluronska kiselina.
The scaffold of claim 1, wherein the said scaffold further comprises an anti-inflammatory compound, an anti-infective compound, a growth factor, a chelator, an antibiotic, a cell population, a pro-angiogenic factor or a combination thereof. 
Struktura platforme sukladno patentnom zahtjevu 1, pri čemu navedena struktura platforme još sadrži protu-upalni spoj, anti-infektivni spoj, faktor rasta, kelator, antibiotik, populaciju stanice, proangiogeni faktor ili njihovu kombinaciju.
The scaffold of claim 1, wherein said scaffold is seeded with a cell population, which population comprises mesenchymal stem cells, osteoblasts, osteocytes, osteoclasts, chondroblasts, chondrocytes, fibroblasts, or a combination thereof. 
Struktura platforme sukladno patentnom zahtjevu 1, pri čemu navedena struktura platforme nasadi s populacijom stanica, čija populacija sadrži mezenhimne matične stanice, osteoblaste, osteocite, osteoklaste, hondroblaste, hondrocite, fibroblaste, ili kombinacija istih.
The scaffold of claim 1, wherein said biocompatible polymer is incorporated within at least a portion of said scaffold. 
Struktura platforme sukladno patentnom zahtjevu 1, pri čemu je navedeni biokompatibilni polimer inkorporiran unutar barem dijela navedene strukture platforme.